A multi-center comparative efficacy and safety study of two different hyaluronic acid fillers for treatment of nasolabial folds in a Chinese population
被引:12
|
作者:
Li, Dong
论文数: 0引用数: 0
h-index: 0
机构:
Peking Univ, Hosp 3, Beijing, Peoples R ChinaPeking Univ, Hosp 3, Beijing, Peoples R China
Li, Dong
[1
]
Sun, Jiaming
论文数: 0引用数: 0
h-index: 0
机构:
Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R ChinaPeking Univ, Hosp 3, Beijing, Peoples R China
Sun, Jiaming
[2
]
Wu, Sufan
论文数: 0引用数: 0
h-index: 0
机构:
Zhejiang Prov Peoples Hosp, Hangzhou, Zhejiang, Peoples R ChinaPeking Univ, Hosp 3, Beijing, Peoples R China
Wu, Sufan
[3
]
机构:
[1] Peking Univ, Hosp 3, Beijing, Peoples R China
[2] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China
[3] Zhejiang Prov Peoples Hosp, Hangzhou, Zhejiang, Peoples R China
Background Nonsurgical injectable treatments, including hyaluronic acid (HA) fillers, are increasingly used in Asian patients. Aims To demonstrate the efficacy and safety of Restylane Lyft compared to Restylane for the correction of nasolabial folds (NLFs). Patients/Methods This was a randomized, evaluator-blinded, split-face, 12-month study conducted in China using Restylane Lyft in the aesthetic correction of moderate to severe NLFs among adult subjects. One NLF was treated with Restylane Lyft, and the opposite NLF with the comparator Restylane. Efficacy outcomes included improvement in the Wrinkle Severity Rating Scale (WSRS) and aesthetic improvement (using the Global Aesthetic Improvement Scale [GAIS] assessed by the subject and blinded evaluator) for each treatment at Months 3, 6 (primary objective based on WSRS), 9, and 12. Safety was evaluated by the incidence of injection site reactions and adverse events (AEs). Results A total of 100 subjects were randomized to the treatments. Noninferiority for Restylane Lyft was established according to blinded evaluation of WSRS at 6 months after last treatment. Similarly, the WSRS improved throughout the study, and the responder rate (improvement in WSRS of >= 1 grade from Baseline) was sustained after 6 months (64% and 65% for NLFs treated with Restylane and Restylane Lyft, respectively). For GAIS after 6 months, improvement was approximately 80% in both groups. No treatment-related serious AEs were reported. The safety profiles were similar between the two treatments. Conclusions Similar to Restylane, Restylane Lyft was effective and well tolerated for treatment of moderate to severe NLFs in this Chinese population.
机构:
Medytox Inc, Seoul, South KoreaUniv Ulsan, Asan Med Ctr, Dept Dermatol, Coll Med, 88,Olymp Ro 43 Gil, Seoul 05505, South Korea
Lee, Woo Shun
Kim, Hak Tae
论文数: 0引用数: 0
h-index: 0
机构:
Univ Ulsan, Asan Med Ctr, Dept Dermatol, Coll Med, 88,Olymp Ro 43 Gil, Seoul 05505, South KoreaUniv Ulsan, Asan Med Ctr, Dept Dermatol, Coll Med, 88,Olymp Ro 43 Gil, Seoul 05505, South Korea
Kim, Hak Tae
Moon, Young Seon
论文数: 0引用数: 0
h-index: 0
机构:
Univ Ulsan, Asan Med Ctr, Dept Dermatol, Coll Med, 88,Olymp Ro 43 Gil, Seoul 05505, South KoreaUniv Ulsan, Asan Med Ctr, Dept Dermatol, Coll Med, 88,Olymp Ro 43 Gil, Seoul 05505, South Korea
Moon, Young Seon
Paik, Seung Hwan
论文数: 0引用数: 0
h-index: 0
机构:
Univ Ulsan, Asan Med Ctr, Dept Dermatol, Coll Med, 88,Olymp Ro 43 Gil, Seoul 05505, South KoreaUniv Ulsan, Asan Med Ctr, Dept Dermatol, Coll Med, 88,Olymp Ro 43 Gil, Seoul 05505, South Korea
Paik, Seung Hwan
论文数: 引用数:
h-index:
机构:
Lee, Woo Jin
Chang, Sung Eun
论文数: 0引用数: 0
h-index: 0
机构:
Univ Ulsan, Asan Med Ctr, Dept Dermatol, Coll Med, 88,Olymp Ro 43 Gil, Seoul 05505, South KoreaUniv Ulsan, Asan Med Ctr, Dept Dermatol, Coll Med, 88,Olymp Ro 43 Gil, Seoul 05505, South Korea
Chang, Sung Eun
Lee, Mi Woo
论文数: 0引用数: 0
h-index: 0
机构:
Univ Ulsan, Asan Med Ctr, Dept Dermatol, Coll Med, 88,Olymp Ro 43 Gil, Seoul 05505, South KoreaUniv Ulsan, Asan Med Ctr, Dept Dermatol, Coll Med, 88,Olymp Ro 43 Gil, Seoul 05505, South Korea
Lee, Mi Woo
Won, Chong Hyun
论文数: 0引用数: 0
h-index: 0
机构:
Univ Ulsan, Asan Med Ctr, Dept Dermatol, Coll Med, 88,Olymp Ro 43 Gil, Seoul 05505, South KoreaUniv Ulsan, Asan Med Ctr, Dept Dermatol, Coll Med, 88,Olymp Ro 43 Gil, Seoul 05505, South Korea
机构:
Chinese Peoples Liberat Army Gen Hosp, Div Plast Surg, Beijing 100853, Peoples R ChinaChinese Peoples Liberat Army Gen Hosp, Div Plast Surg, Beijing 100853, Peoples R China
Yan, Xiaoqing
Xu, Jun
论文数: 0引用数: 0
h-index: 0
机构:
Chinese Peoples Liberat Army Gen Hosp, Div Plast Surg, Beijing 100853, Peoples R ChinaChinese Peoples Liberat Army Gen Hosp, Div Plast Surg, Beijing 100853, Peoples R China
Xu, Jun
Lu, Changsheng
论文数: 0引用数: 0
h-index: 0
机构:
Chinese Acad Med Sci, Plast Surg Hosp, Beijing 100037, Peoples R ChinaChinese Peoples Liberat Army Gen Hosp, Div Plast Surg, Beijing 100853, Peoples R China
Lu, Changsheng
Ma, Yongguang
论文数: 0引用数: 0
h-index: 0
机构:
Peking Univ, Hosp 3, Dept Plast Surg, Beijing, Peoples R ChinaChinese Peoples Liberat Army Gen Hosp, Div Plast Surg, Beijing 100853, Peoples R China
Ma, Yongguang
Li, Wei
论文数: 0引用数: 0
h-index: 0
机构:
Chinese Acad Med Sci, Fu Wai Hosp, Clin Pharmacol Ctr, Div Biometr, Beijing 100037, Peoples R ChinaChinese Peoples Liberat Army Gen Hosp, Div Plast Surg, Beijing 100853, Peoples R China
机构:
Army Med Univ, Dept Plast & Reconstruct Surg, Hosp Affiliated 1, Chongqing, Peoples R ChinaArmy Med Univ, Dept Plast & Reconstruct Surg, Hosp Affiliated 1, Chongqing, Peoples R China
Dai, Xia
Li, Li
论文数: 0引用数: 0
h-index: 0
机构:
Sichuan Univ, West China Hosp, Dept Dermatol, Chengdu, Sichuan, Peoples R ChinaArmy Med Univ, Dept Plast & Reconstruct Surg, Hosp Affiliated 1, Chongqing, Peoples R China
Li, Li
Peterson, Ward
论文数: 0引用数: 0
h-index: 0
机构:
CROMA PHARMA GmbH, Clin Dev, Industriezeile 6, A-2100 Leobendorf, Austria
Ward Peterson Consulting Ltd Liabil Co, Morrisville, NC 27560 USAArmy Med Univ, Dept Plast & Reconstruct Surg, Hosp Affiliated 1, Chongqing, Peoples R China
Peterson, Ward
Baumgartner, Renate R.
论文数: 0引用数: 0
h-index: 0
机构:
CROMA PHARMA GmbH, Clin Dev, Industriezeile 6, A-2100 Leobendorf, AustriaArmy Med Univ, Dept Plast & Reconstruct Surg, Hosp Affiliated 1, Chongqing, Peoples R China
Baumgartner, Renate R.
Huang, Jinmei
论文数: 0引用数: 0
h-index: 0
机构:
Qualtech Consulting Corp, Taipei, TaiwanArmy Med Univ, Dept Plast & Reconstruct Surg, Hosp Affiliated 1, Chongqing, Peoples R China
Huang, Jinmei
Baer-Zwick, Alexandra
论文数: 0引用数: 0
h-index: 0
机构:
CROMA PHARMA GmbH, Regulatory Affairs, Leobendorf, AustriaArmy Med Univ, Dept Plast & Reconstruct Surg, Hosp Affiliated 1, Chongqing, Peoples R China
Baer-Zwick, Alexandra
Hoeller, Sonja
论文数: 0引用数: 0
h-index: 0
机构:
CROMA PHARMA GmbH, Clin Dev, Industriezeile 6, A-2100 Leobendorf, AustriaArmy Med Univ, Dept Plast & Reconstruct Surg, Hosp Affiliated 1, Chongqing, Peoples R China
Hoeller, Sonja
Ivezic-Schoenfeld, Zrinka
论文数: 0引用数: 0
h-index: 0
机构:
CROMA PHARMA GmbH, Clin Dev, Industriezeile 6, A-2100 Leobendorf, AustriaArmy Med Univ, Dept Plast & Reconstruct Surg, Hosp Affiliated 1, Chongqing, Peoples R China
Ivezic-Schoenfeld, Zrinka
Prinz, Martin
论文数: 0引用数: 0
h-index: 0
机构:
CROMA PHARMA GmbH, Clin Dev, Industriezeile 6, A-2100 Leobendorf, AustriaArmy Med Univ, Dept Plast & Reconstruct Surg, Hosp Affiliated 1, Chongqing, Peoples R China